{"id":"folfox-plus-targeted-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX is a combination chemotherapy regimen (5-fluorouracil, leucovorin, and oxaliplatin) that damages cancer cell DNA and prevents replication. The addition of targeted therapy—likely directed at EGFR, VEGF, or other pathway-specific targets—further inhibits tumor growth by blocking specific molecular drivers of cancer progression. This dual approach aims to improve efficacy over chemotherapy alone.","oneSentence":"FOLFOX chemotherapy combined with targeted therapy agents works by inhibiting DNA synthesis and cell division while blocking specific oncogenic signaling pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:15.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (likely metastatic or advanced stage, specific targeted agent and patient population not specified)"}]},"trialDetails":[{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT07483359","phase":"PHASE2","title":"Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03","conditions":"Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus","enrollment":38},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT07381309","phase":"PHASE2","title":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Jun Huang","startDate":"2026-02-01","conditions":"CRC, Liver Metastasis Colon Cancer","enrollment":114},{"nctId":"NCT06631326","phase":"","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","status":"COMPLETED","sponsor":"First Hospital of China Medical University","startDate":"2021-01-01","conditions":"HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma","enrollment":244},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT07309289","phase":"PHASE3","title":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":144},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07224815","phase":"","title":"cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-06-21","conditions":"CRC (Colorectal Cancer)","enrollment":600},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07138885","phase":"PHASE2","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":62},{"nctId":"NCT02885753","phase":"PHASE3","title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-12","conditions":"Colorectal Neoplasms","enrollment":348},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":"Hepatocellular Carcinoma(HCC)","enrollment":300},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT05775146","phase":"PHASE2","title":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-06-18","conditions":"Colorectal Cancer, Liver Metastasis Colon Cancer","enrollment":24},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07000253","phase":"PHASE2, PHASE3","title":"Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01","conditions":"Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma","enrollment":290},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT06641713","phase":"","title":"HAIC Compared With TACE in Huge Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer","enrollment":664},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT03526835","phase":"PHASE1, PHASE2","title":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Merus B.V.","startDate":"2018-05-02","conditions":"Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer","enrollment":523},{"nctId":"NCT04021277","phase":"PHASE1","title":"PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin","status":"TERMINATED","sponsor":"EXACT Therapeutics AS","startDate":"2019-09-17","conditions":"Solid Tumor, Colorectal Cancer","enrollment":11},{"nctId":"NCT06552117","phase":"NA","title":"ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer ( MetaIRM)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-08-10","conditions":"Colorectal Cancer With Liver Metastases","enrollment":50},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06115174","phase":"PHASE4","title":"Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-11-01","conditions":"Metastatic Colorectal Carcinoma","enrollment":44},{"nctId":"NCT04191889","phase":"PHASE2","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-13","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":47},{"nctId":"NCT05797467","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-01","conditions":"Colorectal Cancer, Chemotherapy Effect","enrollment":366},{"nctId":"NCT05815082","phase":"PHASE3","title":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-20","conditions":"Colorectal Cancer, Liver Metastases, Circulating Tumor Cell","enrollment":490},{"nctId":"NCT05797077","phase":"PHASE3","title":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-02-20","conditions":"Colorectal Cancer, Liver Metastases, Circulating Tumor Cell","enrollment":346},{"nctId":"NCT05359406","phase":"PHASE2","title":"A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis","status":"UNKNOWN","sponsor":"LI XIN-XIANG","startDate":"2022-12-01","conditions":"Advanced Rectal Cancer, Distal Metastasis","enrollment":51},{"nctId":"NCT05582278","phase":"PHASE2","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Wen Li","startDate":"2021-01-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05489692","phase":"","title":"HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-09-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":43},{"nctId":"NCT05313282","phase":"PHASE3","title":"A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-15","conditions":"C-staged Hepatocellular Carcinoma in BCLC Classification","enrollment":140},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT03050814","phase":"PHASE2","title":"Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-05","conditions":"Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":30},{"nctId":"NCT01442935","phase":"PHASE2","title":"Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-02","conditions":"Colorectal Cancer","enrollment":256},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT03323424","phase":"PHASE2","title":"Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers","status":"WITHDRAWN","sponsor":"Institut de Cancérologie de la Loire","startDate":"2019-01-01","conditions":"Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer","enrollment":""},{"nctId":"NCT00115765","phase":"PHASE3","title":"PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-06-01","conditions":"Colorectal Cancer","enrollment":1053},{"nctId":"NCT01646554","phase":"PHASE2, PHASE3","title":"Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-12","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer","enrollment":""},{"nctId":"NCT01508000","phase":"PHASE2","title":"Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2013-06","conditions":"Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer","enrollment":44},{"nctId":"NCT01858662","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":4},{"nctId":"NCT00934882","phase":"PHASE1","title":"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-08","conditions":"Colorectal Neoplasms","enrollment":45},{"nctId":"NCT01394120","phase":"PHASE2","title":"Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Sofia Perea, Director Clinical Trials Unit.","startDate":"2011-08","conditions":"Carcinoma, Pancreatic Ductal","enrollment":60},{"nctId":"NCT01453257","phase":"PHASE2","title":"Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Progression Free Survival","enrollment":72},{"nctId":"NCT00443573","phase":"PHASE1, PHASE2","title":"Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer","status":"SUSPENDED","sponsor":"ARCA Biopharma, Inc.","startDate":"2006-12","conditions":"Colon Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFOX plus targeted therapy","genericName":"FOLFOX plus targeted therapy","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX chemotherapy combined with targeted therapy agents works by inhibiting DNA synthesis and cell division while blocking specific oncogenic signaling pathways. Used for Colorectal cancer (likely metastatic or advanced stage, specific targeted agent and patient population not specified).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}